Biopharmaceutical Company 1

Immunomedics is a biopharmaceutical company, now a subsidiary of Gilead Sciences, that specializes in the development of next-generation antibody-drug conjugates (ADCs) for the treatment of various cancers. The company's flagship product, Trodelvy (sacituzumab govitecan-hziy), is a first-in-class ADC targeting the TROP-2 antigen, which is highly expressed in many solid tumors. Trodelvy received FDA accelerated approval in April 2020 for metastatic triple-negative breast cancer (mTNBC) after a Phase 3 trial was halted early due to overwhelming efficacy. In October 2020, Immunomedics was acquired by Gilead Sciences for approximately $21 billion, significantly expanding Gilead's oncology portfolio. The company's proprietary platform technology utilizes humanized monoclonal antibodies linked to a potent chemotherapy payload, SN-38, designed to deliver targeted treatment while minimizing systemic toxicity.